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Associated Pulmonary Embolism
Lehmann R, Suess C, Leus N, et al. Eur Heart J 2009;30:233-41.
Conclusions: Travel-associated pulmonary embolism (PE) has an ex-
cellent long-term prognosis. The risk is low and is strictly dependent on
flight distance.
Summary: Retrospective analyses of travelers arriving at Charles de
Gaulle Airport in Paris and theMadrid-Barajas Airport have determined that
distance traveled is a significant contributing risk for PE associated with air
travel (N Engl J Med 2001;345:779-83 and Arch Intern Med 2003;163:
2766-71). The incidence of PE among passengers traveling5000 km is 1.5
cases/million compared with 0.01 cases/million in those traveling 5000
km. In this article the authors sought to determine the proportion of
travel-associated PE compared with other associated causes of PE and the
long-term prognosis after affected patients. Travel-associated PE was de-
fined as that occurring 2 months of travel.
The study monitored patients with travel-related PE who were admit-
ted to the University of Frankfurt Hospital between 1997 and 2006. This
hospital serves as the primary referral center for Frankfurt International
Airport, the largest airport in Germany and third largest in Europe. Approx-
imately one-third of the passengers arriving at this airport have traveled
5000 km.
Flight distances of passengers with travel-related PE were obtained
from data from FRAPORT AG, the operating company of Frankfurt Inter-
national Airport. Between 1997 and 2006, 257 passengers with acute PE
were admitted to the Frankfurt University Hospital intensive care unit. Of
these, 62 had travel-related PE (45 flight-associated PEs; 17 other travel-
associated PEs). Patients with travel-related PE had a nonsignificantly higher
rate of initial cardiopulmonary resuscitation (4.8% vs 1.5%; P  .153) and a
higher percentage of massive PE (8% vs 3%; P .064). Mortality was similar
in both travel-related and non-travel-related PE (4.8% vs 4.1% respectively,
P  .730). Long-term outcome of travel-related PE patients was excellent
(Kaplan-Meier analysis; log-rank P  .008) vs other entities associated with
PE. Only 13% of patients with travel-related PE had no other identifiable risk
factors, including thrombophilia, 40%; neoplasm, 7%; and family history of
venous thromboembolism or recurrent thromboembolic event, 26%. Travel-
related PE was rare, with one event per 5,000,000 passengers. Flights 5000
km led to a 17-fold increase compared with shorter flights.
Comment: The main points of this study are that travel-related PE is
exceedingly rare and is vanishingly rare in shorter flights. Virtually all patients
with travel-related PE have additional risk factors for venous thromboem-
bolism. Overall, the patients do well, with no difference in hospital mortality
compared with other patients with PE, and the patients with travel-related
PE have a better long-term prognosis.
Long-term Clinical Outcome after Intramuscular Implantation of
Bone Marrow Mononuclear Cells (Therapeutic Angiogenesis by Cell
Transplantation [TACT] Trial) in Patients with Chronic Limb
Ischemia
Matoba S, Tatsumi T, Murohara T, et al. Am Heart J 2008;156:1010-8.
Conclusion: Bone marrow mononuclear cells (BMMCs) can induce
long-term improvement in limb ischemia with extension of the amputation-
free interval.
Summary: Methods of inducing angiogenesis as a treatment for
chronic limb ischemia are being actively investigated. These authors pub-
lished an earlier clinical trial (Lancet 2002;360:427-35) of therapeutic
angiogenesis using BMMCs in patients with chronic limb ischemia second-
ary to peripheral arterial disease (PAD) or thromboangiitis obliterans
(TAO). In that trial, intramuscular implantation of autologous BMMCs
resulted in improvement in transcutaneous oxygen pressure, rest pain,
ankle-brachial index, and pain-free walking time. The current study was
designed to assess long-term safety and clinical outcome after intramuscular
injection of BMMCs in ischemic limbs.
The study included 115 patients, 74 with PAD and 41 with TAO.
After BMMC implantation, patients were evaluated every week for 4
weeks and at 6, 12, 24, and 36 months. Median follow-up time was 25.3
months (range, 0.8-69 months). The 3-year overall survival rates were
80% (95% confidence interval [CI], 68%-91%) in patients with athero-
sclerotic PAD (11 of 74 died) and 100% in 41 patients with TAO. The
amputation-free rate was 60% (95% CI, 46%-74%) in the patients with
PAD and 91% (95% CI, 82%-100%) in those with TAO. The amputation-
free interval was negatively affected by the severity of rest pain and need
for bypass surgery. Significant improvements in leg pain, ulcer size, andpain-free walking distance were maintained for 2 years after follow-up.
Ankle-brachial index and transcutaneous oxygen pressure values did not
change significantly.
Comment: The stimulus for this study was the occasional sudden
death after intramuscular injection of BMMCs (Circulation 2006;114:
2679-84). This study was thus essentially a safety analysis of the patients
treated under previously approved protocols. No control patients were
identified prospectively; therefore, the authors’ conclusion that “the
safety and efficacy are not inferior to the conventional revascularization
therapies” is not really valid. Angiogenesis, however, remains an intriguing
potential therapy for chronic limb ischemia. The overall data thus far are
fairly underwhelming; however, studies like this, with some hints of
improvement in clinically relevant end points, will serve to sustain
interest in angiogenesis. Some approach—probably not one of the cur-
rent approaches—using angiogenesis at least as an adjunct in the treat-
ment of chronic limb ischemia ought to work someday.
Oral Vitamin KVersus Placebo to Correct Excessive Anticoagulation in
Patients Receiving Warfarin: A Randomized Trial
Crowther MA, Ageno W, Garcia D, et al. Ann Intern Med 2009;150:293-
300.
Conclusion: Bleeding is not reduced by low-dose vitamin K therapy in
warfarin recipients with international normalized ratios (INRs) of 4.5 to
10.0.
Summary: Bleeding risk with warfarin therapy increases when the INR
is4.5 (Chest 2008;133:160-98s). In addition, INRs outside the therapeu-
tic range can occur up to one-third to one-half of the time (Chest 2005;127:
1515-22). When patients present with an INR4.5, clinicians may elect to
treat with vitamin K therapy or just withhold warfarin treatment and allow
the INR to drift down over time.
The authors hypothesized patients with INRs 4.5 treated with vita-
min K therapy would have less bleeding complications than those in which
warfarin therapy was merely withheld until the INR returned to therapeutic
levels. They tested their hypothesis by performing a multicenter randomized
trial in nonbleeding patients with INRs of 4.5 to 10.0. Patients were
randomized to receive oral vitamin K (1.25 mg) or placebo. The primary
outcome was the frequency of all forms of bleeding during the first 90 days.
Patients’ primary care givers and those assessing outcomes were blinded to
treatment assignment. Thromboembolism and death were also monitored.
There were 335 patients assigned to oral vitamin K therapy, and 347
were analyzed. There were 369 patients randomly assigned to placebo, and
365 were analyzed. At least one bleeding complication occurred in 56
patients (15.8%) in the vitamin K group and in 60 patients (16.3%) of the
patients in the placebo group, for an absolute difference of0.5 percentage
points (95% confidence interval [CI],6.1 to 5.1 percentage points). Major
bleeding events occurred in nine patients (2.5%) of the vitamin K group and
in four patients (1.1%) of the placebo group (absolute difference, 1.5
percentage points; 95%CI,0.1 to 3.7 percentage points). Four episodes of
thromboembolism (1.1%) occurred in the vitamin K group and three
episodes (0.8%) in the placebo group (absolute difference, 0.3 percentage
points; 95% CI, 1.4 to 2.0 percentage points). One day after treatment,
INR had decreased by 2.8 in the vitamin K group and by 1.4 in the placebo
group (P  .001).
Conclusion: The data indicate that active reduction of the INR by
administration of vitamin K does not reduce bleeding episodes. The data also
indicate administration of vitamin K does not result in increased thrombo-
embolism. The results have significant implications for clinical practice. In
patients with INRs between 4.5 and 10, warfarin therapy should be withheld
and reinstituted once the INR has returned to the desired range. The data
cannot be extrapolated to patients who are bleeding or who present with
INRs10. Overall, the results of the trial should help simplify the manage-
ment of most patients treated with warfarin who present with suprathera-
peutic INR levels.
Plication as Primary Treatment of Steal Syndrome in Arteriovenous
Fistulas
Yaghoubian A, de Virgilio C. Ann Vasc Surg 2009;23:103-7.
Conclusion: Plication is a simple alternative to management of steal
syndrome after construction of an autogenous arteriovenous fistula.
Summary: There is always some steal in patients after creation of an
arteriovenous fistula for hemodialysis. Pathologic steal is uncommon but can
produce devastating complications. Overall incidence is 1% to 9%. In many
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